Startup Bexorg is pioneering a new frontier in pharmaceutical research by utilizing post-mortem human brains for drug development, particularly targeting neurodegenerative diseases. Their innovative BrainEx system provides a life-support environment for donated organs, suppressing electrical activity to prevent consciousness while maintaining metabolic functions. This allows researchers to study drug metabolism and efficacy directly on human brain tissue, offering a potentially more accurate and ethical alternative to traditional methods like animal testing.
Building on years of development and successful trials with pig brains, Bexorg's methodology is poised to significantly impact drug discovery. The company is expanding its research capabilities and working with collaborators like Biohaven, who are already moving drugs developed with Bexorg data into clinical trials. While challenges like the artificial nature of the life-support system remain, Bexorg is also exploring advanced simulation tools to complement its biological models, aiming to accelerate the development of treatments for complex neurological conditions.
